Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Brivaracetam, identified by the CAS number 273106-49-2, is a novel antiepileptic drug (AED) chemically classified as a pyrrolidinone derivative. Its molecular formula is C12H15NO2. Structurally related to levetiracetam, Brivaracetam distinguishes itself through its high affinity for synaptic vesicle protein 2A (SV2A), a presynaptic protein involved in neurotransmitter release. This specific binding mechanism modulates synaptic transmission, thereby stabilizing neuronal membranes and reducing the excessive electrical discharges that characterize epileptic seizures.
Clinically, Brivaracetam is primarily indicated as an adjunctive therapy for partial-onset seizures in adults and pediatric patients aged four years and older who have not achieved adequate seizure control with their current regimen. Unlike some older AEDs, it demonstrates a favorable pharmacokinetic profile with rapid absorption and linear kinetics, allowing for flexible dosing schedules. It exhibits minimal drug-drug interactions because it does not significantly inhibit or induce major cytochrome P450 enzymes, making it a suitable option for patients on complex polytherapy regimens. Furthermore, its high lipophilicity facilitates swift penetration across the blood-brain barrier, leading to a faster onset of action compared to certain peers.
The safety profile of Brivaracetam includes common side effects such as somnolence, dizziness, fatigue, and nausea, which are generally mild to moderate in intensity. Serious adverse events are rare but may include psychiatric symptoms like aggression or mood changes, necessitating careful monitoring during treatment initiation. As a newer generation AED, Brivaracetam offers clinicians a potent tool for managing refractory epilepsy with improved tolerability and a streamlined interaction profile. Ongoing research continues to explore its potential efficacy in broader seizure types and long-term maintenance strategies, solidifying its role in modern neurology practice as a versatile and effective therapeutic agent for diverse patient populations seeking better quality of life through superior seizure management.